Ironwood Pharmaceuticals Receives Average Rating of “Hold” from Brokerages (NASDAQ:IRWD)
Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) have earned a consensus rating of “Hold” from the fourteen ratings firms that are presently covering the stock, AR Network reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $15.30.
Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at 13.10 on Wednesday. Ironwood Pharmaceuticals has a one year low of $8.95 and a one year high of $15.95. The stock has a 50-day moving average of $13.78 and a 200-day moving average of $13.48. The company’s market cap is $1.826 billion.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Monday, August 4th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.02. The company had revenue of $6.84 million for the quarter, compared to the consensus estimate of $15.75 million. During the same quarter in the previous year, the company posted ($0.57) earnings per share. The company’s revenue for the quarter was down 29.9% on a year-over-year basis. On average, analysts predict that Ironwood Pharmaceuticals will post $-1.36 earnings per share for the current fiscal year.
A number of research firms have recently commented on IRWD. Analysts at Zacks reiterated a “neutral” rating on shares of Ironwood Pharmaceuticals in a research note on Wednesday, August 6th. They now have a $14.00 price target on the stock. Separately, analysts at Leerink Swann reiterated a “market perform” rating on shares of Ironwood Pharmaceuticals in a research note on Tuesday, August 5th. They now have a $16.00 price target on the stock, up previously from $15.00. Finally, analysts at Furey Research Partners initiated coverage on shares of Ironwood Pharmaceuticals in a research note on Wednesday, July 9th. They set a “buy” rating and a $20.00 price target on the stock.
Ironwood Pharmaceuticals, Inc is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines.